Technology
Health
Biotechnology

Recro Pharma

$9.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-0.40%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Recro Pharma and other stocks, options, ETFs, and crypto commission-free!

About REPH

Recro Pharma, Inc. Common Stock, also called Recro Pharma, is a pharmaceutical company, which engages in the research and development of non-opioid therapeutics for the treatment of acute post operative pain. Read More It operates through the Acute Care, and Contract Development and Manufacturing (CDMO) business segment. The Acute Care segment focuses on developing innovative products for hospital and related settings. The CDMO segment leverages the company's formulation expertise to develop and manufacture pharmaceutical products using the company's proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Its products include Meloxicam, Dexmedetomidine, and Fadolmidine. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Malvern, PA.

Employees
260
Headquarters
Malvern, Pennsylvania
Founded
2007
Market Cap
219.78M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
156.87K
High Today
$10.01
Low Today
$9.81
Open Price
$9.92
Volume
128.28K
52 Week High
$10.69
52 Week Low
$5.07

Collections

Technology
Health
Biotechnology
Pharmaceutical
Research And Development
Therapy
Manufacturing
2014 IPO

REPH Earnings

-$1.34
-$0.93
-$0.51
-$0.10
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.